EMA launches survey on pharma companies’ Brexit preparedness

The European Medicines Agency (EMA) has launched a survey directly to marketing authorisation holders of centrally authorised medicines that are located in the United Kingdom (UK), or who have quality control, batch release, and/or import manufacturing sites or a qualified person for pharmacovigilance (QPPV) or pharmacovigilance system master file (PSMF) in the UK. The survey concerns company’s plans to submit transfers, notifications or variations to their marketing authorisations in the context of the UK’s withdrawal from the European Union (EU).

The survey deadline is 09 February 2018.

For more information please click here.

Tagged with

Published 25. January 2018 in News EU, News UK